Cover Image
市場調查報告書

麩質過敏症:開發中產品分析

Celiac Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232849
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
麩質過敏症:開發中產品分析 Celiac Disease - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 82 Pages
簡介

麩質過敏症又被稱之為麩質過敏性腸症,是攝取到含有麩質的食物時產生因為小腸黏膜受損而引發的消化及自體免疫性疾病,症狀有消化不良、重度的皮膚發疹、缺鐵性貧血、抽搐、肌肉骨骼系統不協調等。第一型糖尿病、唐氏症、自體免疫性甲狀腺疾病、乾燥症(修格蘭氏症候群)患者有容易引發此症的傾向。

本報告提供麩質過敏症的治療藥開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

麩質過敏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

麩質過敏症:企業開發中的治療藥

麩質過敏症:大學/機關研究中的治療藥

麩質過敏症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

麩質過敏症:企業開發中的產品

麩質過敏症:大學/機關研究中的產品

麩質過敏症的治療藥開發作的企業

  • Alvine Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyra Biotech AG
  • Avaxia Biologics, Inc.
  • Calypso Biotech SA
  • enGene, Inc
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • ImmusanT, Inc.
  • Innovate Biopharmaceuticals, Inc.
  • Intrexon Corporation
  • Sanofi
  • Zedira GmbH

麩質過敏症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AMG-714
  • AVX-176
  • Biologic to Target Gluten and IL-10 for Celiac Disease
  • Biologics to Antagonize HLA-DQ2 for Celiac Disease
  • Biologics to Inhibit Transglutaminase 2 for Celiac Disease
  • BNZ-1322
  • CALY-002
  • Enzyme for Celiac Disease
  • Enzymes for Celiac Disease
  • ERW-1041E
  • GBR-830
  • larazotide acetate
  • latiglutenase
  • Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology and Gastrointestinal Disorders
  • Nexvax-2
  • Oligonucleotides for Celiac Disease
  • Peptide for Celiac Disease
  • Recombinant Protein for Celiac Disease and Type-1 Diabetes
  • RG-7625
  • Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes
  • Vaccine for Celiac Disease
  • ZED-1227
  • ZED-754

麩質過敏症:最近的開發平台趨勢

麩質過敏症:暫停中的計劃

麩質過敏症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8529IDB

Summary

Global Markets Direct's, 'Celiac Disease - Pipeline Review, H2 2016', provides an overview of the Celiac Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Celiac Disease
  • The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects
  • The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Celiac Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Celiac Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Celiac Disease Overview
  • Therapeutics Development
    • Pipeline Products for Celiac Disease - Overview
    • Pipeline Products for Celiac Disease - Comparative Analysis
  • Celiac Disease - Therapeutics under Development by Companies
  • Celiac Disease - Therapeutics under Investigation by Universities/Institutes
  • Celiac Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Celiac Disease - Products under Development by Companies
  • Celiac Disease - Products under Investigation by Universities/Institutes
  • Celiac Disease - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Amyra Biotech AG
    • Avaxia Biologics, Inc.
    • Calypso Biotech SA
    • enGene, Inc
    • F. Hoffmann-La Roche Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • ImmusanT, Inc.
    • Innovate Biopharmaceuticals, Inc.
    • Intrexon Corporation
    • Sanofi
    • Zedira GmbH
  • Celiac Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMG-714 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVX-176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ERW-1041E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBR-830 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • larazotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latiglutenase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Central Nervous System and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nexvax-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nexvax-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Celiac Disease and Type-1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Celiac Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZED-1227 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZED-754 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Celiac Disease - Dormant Projects
  • Celiac Disease - Product Development Milestones
    • Featured News & Press Releases
      • May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease
      • May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016
      • May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease
      • Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II
      • Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting
      • Sep 03, 2015: Glenmark's Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe
      • Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium
      • Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
      • Nov 19, 2014: ImmusanT's Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa's Top 10 Autoimmune/Anti-Inflammatory Projects to Watch
      • Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury
      • Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease
      • Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease
      • Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
      • Apr 19, 2013: ImmusanT's Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases
      • Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Celiac Disease, H2 2016
  • Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Celiac Disease - Pipeline by Amgen Inc., H2 2016
  • Celiac Disease - Pipeline by Amyra Biotech AG, H2 2016
  • Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2016
  • Celiac Disease - Pipeline by Calypso Biotech SA, H2 2016
  • Celiac Disease - Pipeline by enGene, Inc, H2 2016
  • Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Celiac Disease - Pipeline by ImmusanT, Inc., H2 2016
  • Celiac Disease - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016
  • Celiac Disease - Pipeline by Intrexon Corporation, H2 2016
  • Celiac Disease - Pipeline by Sanofi, H2 2016
  • Celiac Disease - Pipeline by Zedira GmbH, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Celiac Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Celiac Disease, H2 2016
  • Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top